Once-daily extended-release versus twice-daily standard-release tacrolimus in kidney transplant recipients: A systematic review

Transplantation

Volumn 95, Issue 9, 2013, Pages 1120-1128

  Ho, Elaine T L ^a,b   Wong, Germaine ^a,c,d   Craig, Jonathan C ^c,d   Chapman, Jeremy R ^a  

^a WESTMEAD HOSPITAL   (Australia)

^b TSEUNG KWAN O HOSPITAL   (Hong Kong)

^c UNIVERSITY OF SYDNEY   (Australia)

^d CHILDREN S HOSPITAL AT WESTMEAD   (Australia)

Author keywords

Biopsy proven acute rejection; Compliance; Immunosuppressant; Kidney transplantation; Nonadherence; Prolonged release; Tacrolimus

Indexed keywords

ALEMTUZUMAB; AZATHIOPRINE; BASILIXIMAB; CORTICOSTEROID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT REJECTION; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; SYSTEMATIC REVIEW;

BACTERIAL INFECTIONS; DRUG ADMINISTRATION SCHEDULE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TACROLIMUS;

EID: 84877249792     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e318284c15b     Document Type: Review

References (42)

1. Meier-Kriesche HU, Li S, Gruessner RW, et al. Immunosuppression: evolution in practice and trends, 1994Y2004. Am J Transplant 2006; 6: 1111.
2. First MRF. Modified release tacrolimus. Yonsei Med J 2004; 45: 1127.
3. Chisholm MAM. Modified-release tacrolimus. Ann Pharmacother 2006; 40: 270.
4. Hardinger KL, Park JM, Schnitzler MA, et al. Pharmacokinetics of tacrolimus in kidney transplant recipients: twice daily versus once daily dosing. Am J Transplant 2004; 4: 621.
5. Didlake RH, Dreyfus K, Kerman RH, et al. Patient noncompliance: a major cause of late graft failure in cyclosporine-treated renal transplants. Transplant Proc 1988; 20: 63.
6. Pinsky BW, Takemoto SK, Lentine KL, et al. Transplant outcomes and economic costs associated with patient noncompliance to immunosuppression. Am J Transplant 2009; 9: 2597.
7. Nevins TE, Thomas W. Quantitative patterns of azathioprine adherence after renal transplantation. Transplantation 2009; 87: 711.
8. Vlaminck H, Maes B, Evers G, et al. Prospective study on late consequences of subclinical non-compliance with immunosuppressive therapy in renal transplant patients. Am J Transplant 2004; 4: 1509.
9. Michelon TF, Piovesan F, Pozza R, et al. Noncompliance as a cause of renal graft loss. Transplant Proc 2002; 34: 2768.
10. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296.
11. Chisholm-Burns MA, Spivey CA, Rehfeld R, et al. Immunosuppressant therapy adherence and graft failure among pediatric renal transplant recipients. Am J Transplant 2009; 9: 2497.
12. Diez OB, Alonso AM, Aguado FS, et al. Three-month experience with tacrolimus once-daily regimen in stable renal allografts. Transplant Proc 2009; 41: 2323.
13. Andres A, Delgado-Arranz M, Morales E, et al. Extended-release tacrolimus therapy in de novo kidney transplant recipients: singlecenter experience. Transplant Proc 2010; 42: 3034.
14. Gallego-Valcarce E, Ortega-Cerrato A, Llamas-Fuentes F, et al. Conversion to tacrolimus extended-release formulation: short-term clinical results. Transplant Proc 2009; 41: 2326.
15. Kramer BK, Charpentier B, Backman L, et al. Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study. Am J Transplant 2010; 10: 2632.
16. Wlodarczyk ZS. Pharmacokinetics for once-versus twice-daily tacrolimus formulations in de novo kidney transplantation: a randomized, openlabel trial. Am J Transplant 2009; 9: 2505.
17. Cabello MG. Pharmacokinetics of once- versus twice-daily tacrolimus formulations in kidney transplant patients receiving expanded criteria deceased donor organs: a single-center, randomized study. Transplant Proc 2010; 42: 3038.
18. Alloway RM. A phase 2 randomized study of the pharmacokinetics, safety and efficacy of LCP-Tacro tablets once-a-day vs Prograf capsules twice-a-day in de novo kidney transplants. Am J Transplant 2011; Conference: April.
19. Albano LB. Efficacy and optimised dosing in tacrolimus prolonged release vs tacrolimus immediate release-based therapy in renal transplantationVthe OSAKA study. Am J Transplant 2011; Conference: April.
20. Silva J. One-year results with extended-release tacrolimus/MMF, tacrolimus/MMF and cyclosporine/MMF in de novo kidney transplant recipients. Am J Transplant 2007; 7: 595.
21. Crespo MM. De novo kidney transplant recipients need higher doses of Advagraf compared with Prograf to get therapeutic levels. Transplant Proc 2009; 41: 2115.
22. Imanishi Y, Matsui K, Ishida K, et al. Pharmacokinetic properties of a once-daily formulation of tacrolimus in patients with renal transplantation. Arzneimittelforschung 2011; 61: 191.
23. de Jonge HK. Reduced C0 concentrations and increased dose requirements in renal allograft recipients converted to the novel oncedaily tacrolimus formulation. Transplantation 2010; 90: 523.
24. Alloway R, Steinberg S, Khalil K, et al. Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extendedrelease formulation in stable kidney transplant recipients. Transplantation 2007; 83: 1648.
25. Shapiro RM. Alemtuzumab preconditioning with tacrolimus monotherapy in kidney transplant recipients: impact of once daily vs bid tacrolimus. Am J Transplant 2010; Conference: April.
26. Guirado L, Cantarell C, Franco A, et al. Efficacy and safety of conversion from twice-daily to once-daily tacrolimus in a large cohort of stable kidney transplant recipients. Am J Transplant 2011; 11: 1965.
27. Tinti F, Mecule A, Poli L, et al. Improvement of graft function after conversion to once daily tacrolimus of stable kidney transplant patients. Transplant Proc 2010; 42: 4047.
28. Hougardy JM, Broeders N, Kianda M, et al. Conversion from Prograf to Advagraf among kidney transplant recipients results in sustained decrease in tacrolimus exposure. Transplantation 2011; 91: 566.
29. Bowman LJS. Conversion to once daily brand name Prograf is safe and effective. Am J Transplant 2011; Conference: April.
30. Wu M-JC. Significant lower trough level after conversion from Prograf to Advagraf in stable kidney transplant recipients. Am J Transplant 2011; Conference: Apri.l.
31. Mecule A, Poli L, Nofroni I, et al. Once daily tacrolimus formulation: monitoring of plasma levels, graft function, and cardiovascular risk factors. Transplant Proc 2010; 42: 1317.
32. Tong A, Howell M, Wong G, et al. The perspectives of kidney transplant recipients on medicine taking: a systematic review of qualitative studies. Nephrol Dial Transplant 2011; 26: 344.
33. Easterbrook PJ, Berlin JA, Gopalan R, et al. Publication bias in clinical research. Lancet 1991; 337: 867.
34. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088.
35. Lexchin J, Bero LA, Djulbegovic B, et al. Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 2003; 326: 1167.
36. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009; 151: 264, W64.
37. Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011; 343: d5928.
38. von EE, Altman DG, Egger M, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Bull World Health Organ 2007; 85: 867.
39. Sanderson S, Tatt ID, Higgins JP. Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography. Int J Epidemiol 2007; 36: 666.
40. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177.
41. Higgins JP, Thompson SG. Quantifying heterogeneity in a metaanalysis. Stat Med 2002; 21: 1539.
42. Duval S, Tweedie R. Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000; 56: 455.